An interventional study of Doraya catheter in Acute Heart Failure, sponsored by Revamp Medical Ltd.. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-05-06.
Sponsored by Revamp Medical Ltd. · Not applicable, Interventional, and Treatment
Safety and performance evaluation of the Doraya catheter in patients admitted with AHF.
The purpose of this clinical investigation is to evaluate the safety and performance of the Doraya catheter in patients admitted with AHF, presenting persistent volume over load and poor response to diuretic treatment.
5,697 studies on the registry are indexed under Heart Failure; 1,219 are open to participants now.
This study's enrollment of 9 is below the median of 72 across 3,733 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Revamp Medical Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
AHF patient treatment with the Doraya catheter
Device: Doraya catheter
Temporary deployment of the Doraya catheter in AHF patients.
Device or procedure related Serious Adverse Event (SAE) rate through 60 days
SAE as defined by ISO 14155
Time frame: 60 days
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Revamp Medical Ltd.